anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
A human ubiquitin conjugating enzyme, designated hUBC-9, its full amino acid sequence, and nucleic acid polymers which encode hUBC-9 are disclosed. In addition to having functional ubiquitin conjugating activity, this enzyme has transcriptional repressor activity which is independent of the conjugating activity. The conjugating activity of hUBC-9 enhances transcription through degradation of transcription suppressor proteins such as WT1, and possibly, of hUBC-9 itself. The repressor activity of hUBC-9 suppress gene transcription, probably by disrupting the transcriptional initiation complex through specific interactions with the DNA binding region of the TATA binding protein (TBP). In use, hUBC-9, yUBC-9 and other ubiquitin conjugating enzymes having repressor activity can be fused to proteins having a DNA binding domain, such as Gal4, or used in conjunction with reppressors such as Wilm&#39;s tumor suppressor gene product, WT1. Such enzymes and the nucleic acid polymers encoding them can be used for regulating transcription of a target gene in both pharmaceutical and non-pharmaceutical applications.
Amyloid β (Aβ) aggregates are considered as possible targets for therapy and/or diagnosis of Alzheimer disease (AD). It has been previously shown that curcumin targets Aβ plaques and interferes with their formation, suggesting a potential role for prevention or treatment of AD. In the present invention, curcumin-derivatives with improved physicochemical properties were synthesized and a &#34;click chemistry&#34; as well as a conventional liposome preparation method, were used to generate nanoliposomes decorated with the curcumin derivatives. These derivatives were designed to maintain the planar structure required for interaction with Aβ, as directly confirmed by Surface Plasmon Resonance experiments. Surface Plasmon Resonance experiments, measuring the binding of flowing liposomes to immobilized Aβ1-42, indicated that the liposomes exposing curcumin derivatives have extremely high affinity for Aβ1-42 fibrils (1-5 nM), likely because of the occurrence of multivalent interactions. The present invention describes the synthesis of the curcumin derivatives and the preparation and characterization of new nanoliposomes with a very high affinity for Aβ1-42 fibrils, to be exploited as vectors for the targeted delivery of new diagnostic and therapeutic molecules for AD.
Methods and compositions are provided which contains preparations of calcium chelators, bisphosphonates, antibiotics, antimicrobial agents, cytostatic agents, calcium ATPase and pyrophosphatase pump inhibitors, calcium phosphate-crystal dissolving agents, agents effective against calcium phosphate-crystal nucleation and crystal growth, and/or a combination of supportive agents and which may be used for treating and or reducing pathological calcifications, the growth of Nanobacteriu and calcification-induced diseases including, but not limited to, Arteriosclerosis, Atherosclerosis, Coronary Heart Disease, Chronic Heart Failure, Valve Calcifications, Arterial Aneurysms, Calcific Aortic Stenosis, Transient Cerebral Ischemia, Stroke, Peripheral Vascular Disease, Vascular Thrombosis, Dental Plaque, Gum Disease (dental pulp stones), Salivary Gland Stones, Chronic Infection Syndromes such as Chronic Fatigue Syndrome, Kidney and Bladder Stones, Gall Stones, Pancreas and Bowel Diseases (such as Pancreatic Duct Stones, Crohn&#39;s Disease, Colitis Ulcerosa), Liver Diseases (such as Liver Cirrhosis, Liver Cysts), Testicular Microliths, Chronic Calculous Prostatitis, Prostate Calcification, Calcification in Hernodialysis Patients, Malacoplakia, Autoimmune Diseases. Erythematosus, Scleroderma. Derrnatomyositis, Antiphospholipid Syndrome, Arteritis Nodosa, Thrombocvtopenia, Hemolytic Anemia, Myelitis, Livedo Reticularis, Chorea, Migraine, Juvenile Dermatomyositis, Grave&#39;s Disease, Hypothyreoidism, Type I Diabetes Mellitus. Addison&#39;s Disease, Hypopituitarism, Placental and Fetal Disorders, Polycystic Kidney Disease, Glomerulopathies, Eye Diseases (such as Corneal Calcifications. Cataracts. Macular Degeneration and Retinal Vasculature-derived Processes and other Retinal Degenerations. Retinal Nerve Degeneration, Retinitis, and Iritis), Ear Diseases (such as Otosclerosis, Degeneration of Otoliths and Symptoms from the Vestibular Organ and Inner Ear (Vertigo and Tinnitus), Thyroglossal Cysts, Thyroid Cysts, Ovarian Cysts, Cancer (such as Meningiomas, Breast Cancer, Prostate Cancer, Thyroid Cancer, Serous Ovarian Adenocarcinoma), Skin Diseases (such as Calcinosis Cutis, Calciphylaxis, Psoriasis, Eczema, Lichen Ruber Planus), Rheumatoid Arthritis, Calcific Tenditis, Osteoarthritis, Fibromyalgia, Bone Spurs, Diffuse Interstitial Skeletal Hyperostosis, Intracranial Calcifications (such as Degenerative Disease Processes and Dementia), Erythrocyte-Related Diseases involving Anemia, Intraerythrocytic Nanobacterial Infection and Splenic Calcifications, Chronic Obstructive Pulmonary Disease, Broncholiths, Bronchial Stones, Neuropathy, Calcification and Encrustations of Implants, Mixed Calcified Biofilms,.and Myelodegenerative Disorders (such as Multiple Sclerosis, Lou Gehrig&#39;s and Alzheimer&#39;s Disease) in humans and animals. The method comprises administering the various classes of compositions of the present invention, which together effectively inhibit or treat the development of calcifications in vivo.
PROBLEM TO BE SOLVED: To obtain a composition for film coating, attempting smooth deglutition of oral solid preparation without feeling the sense of greasiness and the sense of slime, capable of forming a coated film excellent in elution of a main medicine of the coated oral solid preparation. SOLUTION: This composition for film coating is obtained by formulating methyl cellulose with a saccharide and provides the surface of an oral solid preparation with lubricating properties. The methyl cellulose has preferably &lt;=20 mm&lt;2&gt; /sec dynamic viscosity at 20 deg.C at 2% aqueous solution of methyl cellulose. Preferably the amount of the saccharide is 20-300 pts.wt. of based on 100 pts.wt. of methyl cellulose.
PCT No. PCT/JP96/00980 Sec. 371 Date Nov. 26, 1996 Sec. 102(e) Date Nov. 26, 1996 PCT Filed Apr. 10, 1996 PCT Pub. No. WO96/32101 PCT Pub. Date Oct. 17, 1996The present invention relates to a cancer metastasis inhibitor comprising a benzoic acid derivative as an active ingredient represented by the formula (I)    &lt;IMAGE&gt;  (I)  wherein R1, R2, R3 and R4 are the same or different and each represents hydrogen atom, hydroxyl group or trimethylsilyl group, or R3 and R4 are bonded to each other to form a tetramethylene group substituted with lower alkyl group, and X represents group -COCH=C(OH)-, group -NHCO- or group -CONH-, provided that when R3 and R4 are bonded to each other to form a tetramethylene group substituted with lower alkyl group, X is group -COCH=C(OH)- or group -CONH-, use of the benzoic acid derivative for preparing the cancer metastasis inhibitor and method of inhibiting cancer metastasis, characterized in that an effective amount of the benzoic acid derivative is administered to a mammalian animal for inhibiting metastasis of cancer. The benzoic acid derivative represented by the above formula (I) has extremely good metastasis inhibiting properties.
&lt;P&gt;PROBLEM TO BE SOLVED: To facilitate understanding of examination status information of a patient having visited a hospital.  &lt;P&gt;SOLUTION: In a small-scale diagnostic system 1, a medical image management device 3 is connected to a client terminal 7 via a communication network 8 for enabling data communication therebetween, and the medical image management device 3 displays the examination status information indicating an examination state of the patient stored in a storage part 33, on a patient information list display screen 350 of a display part 35. A change window 49 is displayed on the patient information list display screen 350 by an input from an operation part 34, and the examination status information is changed therein by selecting a button. The changed examination status information is reflected onto the patient information list display screen 350 displayed on the display part 35 or a display part 75. The examination status information is indtructed to be changed also in an operation part 74 of the client terminal 7, by the same manner.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
The invention comprises compounds of the general formula &lt;FORM:1000896/C2/1&gt; in which n1 and n2 each represent zero or unity, X represents a hydroxy, alkoxy, amino or hydrazino group or an alkylamino or dialkylamino group which may be long-chain in character (i.e. containing at least 10 carbon atoms) and each R represents a residue of an a -amino carboxylic acid devoid of its a -amino and carboxylic groups with at least one such residue carrying an amino and/or guanidino group which may in turn carry a long-chain aliphatic acyl substituent and in which A represents an amino group or an amino group which carries a long-chain acyl substituent, and acid addition salts thereof; there being at least one of said long-chain moieties present in the molecule and the preparation thereof by condensing the appropriate protected a -amino carboxylic acid with a protected a -amino acid or dipeptide or tripeptide or the appropriate protected dipeptide with an a -amino acid or dipeptide in the presence of a condensing agent, or reacting the appropriate protected a -amino carboxylic acid or dipeptide or tripeptide starting material in its mixed anhydride, azide, activated ester, or acid chloride form with the other component in the absence of a condensing agent, hydrolysing the terminal carboxyl function to a free carboxyl group or converting it into an amido, N-alkyl-amido, N,N-dialkylamido or hydrazido group, removing the protective groups, and, if desired, converting the resulting peptide into a salt; the long-chain acyl group, if not already present in the molecule, being effected by interchange with a protecting group which can be selectively split off.  Carboxyl groups are protected prior to the condensation reaction involving them per se by conversion into their esters or amides or by salt formation. Free amino groups may be protected by conversion into benzyloxycarbonylamino groups by formylation, or by conversion into phthalyl derivatives or by the introduction of the long-chain acyl group.  Compounds may contain more than one N-protecting group and if these are different the groups may be removed separately.  Na  - Palmitoyl - (Nd  - carbobenzyloxy) - L-ornithine is prepared from the N-protected ornithine and palmitoyl chloride Na -palmitoyl-Ne -carbobenzyloxy-L, -D- and -DL-lysine; Na -stearyl-,-lauryl-, and -caproyl-Ne -carbobenzyloxy-L - lysine, and Na  - palmitoyl - Na  - carbobenzyloxy - L - diamino butyric acid.  Ne -Palmitoyl-L-lysine methylester is prepared by reacting the copper complex of L-lysine with palmitoyl chloride to give Ne -palmitoyl-L-lysine and esterifying this with methanol.  Similarly is prepared Na -palmitoyl L-diamino-butyric and its methyl ester.  Ne -Phthaloyl-L-lysine ethyl ester hydrochloride prepared from the free acid is reacted with 10-andecenoic acid in the presence of dicyclohexyldicarbodimide to give Na  - (10 - undecenoyl) - (Ne  - phthaloyl) - L lysine ethyl ester and, on hydrolysis, the free acid.  Na  - Benzyloxycarbonyl - Ne  - phthaloyl-L-lysine is prepared from the Ne -phthaloyl-L-lysine and benzyloxycarbonyl chloride.  Specifications 1,000,899 and 1,000,900 are referred to.
Atopy has been known as one of the incurable diseases without a sure preventive or treatment method for both babies and adults. This invention is the first that enables the prevention and treatment of baby atopy using green tea and lactobaci llus digestives. According to the invention, by addition of 0.02 ~ 1.3 wt % of green tea, and for the purpose of preventing side effects from green tea and increasing curative efficacy, addition of 0.15 ~ 10 wt %(0.009 ~ 0.8wt % on pure lactobaci llus basis) of lactobaci llus digestives made up of lactobaci llus or butyric-acid bacteria or yeast fungi to baby dry milk or weaning food, we can prevent and treat baby atopy. 0.1 ~ 1.3 wt % of green tea content is adequate for the cure of babies&#39; atopy and 0.02 ~ 0.1 wt % of green tea content is adequate for the prevention and aftercare of baby atopy. Green tea or green tea extract and lactobaci llus digestives are added during manufacturing process of the baby dry milk or weaning food. As a result of the experiment the invention was applied to, most of the babies who participated in the experiment either were completely cured of atopy or showed significant improvement within about a month.
PURPOSE: A composition containing Artemisia princeps or Artemisia iwayomogi extract is provided to promote PPAR-delta and to prevent and relieve dementia or Parkinson&#39;s disease. CONSTITUTION: A composition for improving muscle metabolism and memory contains 1-80 weight% of Artemisia princeps extract. The composition controls an enzyme expression which promotes intramuscular fat and glycosylation. The composition also prevents and relieves dementia or Parkinson&#39;s disease. A method for preparing the extract of Artemisia princeps or Artemisia iwayomogi comprises: a step of adding water or organic solvent to Artemisia princeps or Artemisia iwayomogi and stirring at 70-80 degrees Celsius for 3 hours twice; a step of filtering using Wahtman No.1 filter; and a step of freeze-drying to obtain solid powder. The organic solvent is ethanol, methanol, butanol, ether, ethyl acetate, and chloroform.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a single-strand Fv (sFv) polypeptide defining a binding site which exhibits the immunological binding properties of an immunoglobulin molecule which binds c-erbB-2 or a c-erbB-2-related tumor antigen.  &lt;P&gt;SOLUTION: The single-strand Fv (sFv) polypeptide defining a binding site which exhibits the immunological binding properties of an immunoglobulin molecule which binds c-erbB-2 or a c-erbB-2-related tumor antigen. The sFv includes at least two polypeptide domains connected by a polypeptide linker spanning the distance between the C-terminus of one domain and the N-terminus of the other. The amino acid sequence of each of the polypeptide domains includes a set of complementarity determining regions (CDRs) interposed between a set of framework regions (FRs). The CDRs participates in immunological binding to the c-erbB-2 or c-erbB-2-related tumor antigen.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PURPOSE:To produce the subject powdery saccharide capable of readily handling, excellent in moisture absorption resistance and fluidity and useful as a mixed sweetening, etc., by adding a seed crystal to a high-concentration solution of a specified abundantly panose-containing saccharide, depositing panose and collecting the objective powdery saccharide having &gt;=a prescribed crystallinity. CONSTITUTION:A seed crystal is added to a high-concentration solution of an abundantly panose-containing saccharide containing not only panose in an amount of 48-93wt.% based on solid matter but also other oligosaccharides, etc., so that panose may be deposited. The resultant deposited material is used as a mass-kit and powdered and a powdery saccharide showing &gt;=19% crystallinity measured by powder X-ray diffractometory is collected, thus obtaining the objective powdery saccharide. In addition, the obtained saccharide shows 16.4 deg., 18.2 deg., 18.5 deg. and 20.8 deg. as the angle of diffraction (28%theta).
Prepn. of human immune response suppressor (hIRS) is effected by multiplication of human derived hIRS producing cell with transplantation into warm-blooded animal except human, or with supply of the animal&#39;s body fluid, and producing hIRS from the obtd. cell. hIRS inducer is used at the producing hIRS. hIRS is used as drug for allergic and autoimmune diseases, and anaphylaxie shock and as inhibitor for immuno rejection at transplantation. This prepn. gives stable and fast multiplication without expensive medium, with easy control.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a glycoside having dopamine 2 neuron activating action and existing in living body.  &lt;P&gt;SOLUTION: The glycoside has Fucal-2Gal, Galb1-4GlcNAc and GalNAc a1-3GalNAc structures at the terminals of a polymer skeleton of mannose partially refined from tobacco and has dopamine neuron activating action. A glycoside derivative has Fucal-2Gal, Galb1-4GlcNAc, GalNAc a1-3GalNAc structures at the terminals of a polymer skeleton of mannose partially refined from tobacco and has dopamine neuron activating action. A therapeutic agent for melancholia/Parkinson&#39;s disease and their diagnostics are each obtained by utilizing the glycoside or its derivative. A substitute medicine for tobacco dependence is obtained by utilizing the glycoside or its derivative.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To enable to easily obtain and preset an appropriate test protocol for each test by sharing test protocols among medical diagnostic imaging apparatuses when a wide variety of tests are performed with medical diagnostic imaging apparatuses.  &lt;P&gt;SOLUTION: X-ray diagnostic imaging apparatuses 101A and 102B of medical institutions A and B, respectively, and an information delivery server 201 are linked by a wide-area network 301. Test protocols including information on X-ray diagnostic imaging are recorded in the server 201, and the server searches for and provides a test protocol upon request of the X-ray diagnostic imaging apparatuses 101A and 102B. Consequently, each of the diagnostic apparatuses 101A and 102B can use test protocols established by the other apparatus besides test protocols established by itself. Since the server 201 has a search function, the diagnostic apparatuses 101A and 102B are able to easily obtain any information among the recorded test protocols.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
PROBLEM TO BE SOLVED: To industrially obtain a cod liver oil having a specific peroxide value and a specified aldehyde value, scarcely generating a smell and having excellent stability. SOLUTION: This cod liver oil has a peroxide value of &lt;=5 meq/kg and an aldehyde value of &lt;=0.020 mmol/g. The cod liver oil is obtained by subjecting cod liver oil to a peroxide-removing treatment, adding 0.01-1 pt. of one or more antioxidizing agents selected from the group consisting of dibutylhydroxytoluene, butylhydroxyanisole, citric acid, ascorbic acid and their esters to 100 pts. of the treated cod liver oil, and subsequently subjecting the mixture to a deodorization treatment using a thin film distillation device at a deodorization temperature of 80-120 deg.C under a vacuum degree of &lt;=2 mmHg. The retention time of the cod liver oil is preferably 2-20 sec.  The peroxide-removing treatment is carried out by adding an adsorption treatment agent such Japanese acid white clay or activated white clay preferably in an amount of 0.5-10 pts.wt. to 100 pts.wt. of the cod liver oil, further adding a filtration auxiliary preferably in an amount of 50-100 wt.% based on the adsorption treatment agent and subsequently filtering the treated mixture.
PURPOSE:To provide a stable bath liquid composition giving increased concentration at the surface of the skin and exhibiting excellent warmth-retaining effect, by adding a cationic surfactant and an organic warmth-retaining agent to an aqueous dispersion of a specific nonionic surfactant vesicle. CONSTITUTION:The objective composition is produced by mixing (A) an aqueous dispersion of nonionic surfactant vesicle consisting of (i) 100pts.wt. of an ethoxylate selected from polyoxyethylene (hardened) castor oil (preferably having an added ethylene oxide molar number of 8-15) and (ii) 3-30pts.wt., preferably 5-25pts.wt. of a long-chain fatty acid sorbitan polyester (preferably having an esterification degree of 2.8-3.2) with (B) &lt;=30wt% (based on the whole surfactants) cationic surfactant (e.g. long-chain alkylamine, monoalkylated quaternary ammonium salt, etc.) and (C) an organic warmth-retaining agent such as essential oil, vegetable extract, etc. Positive surface charges are imparted to the vesicle particles to improve the adsorptivity of the vesicle to the surface of the skin.
PURPOSE:To manufacture a composite material for organism having merits of both the materials and excellent in wt. and toughness by using Al2O3 as basis particles and Ti as fine particles, covering and joining the basis particles with plural fine particles and forming a capsule granule. CONSTITUTION:Al2O3 (&lt;= about 100mum particle diameter) is made to the basis particles 16 and mechanical alloying is executed to the fine particles 17 of Ti (&lt;= about 10mu particle diameter on the surface of this basis particle 16 and the fine particles are fixed to the basis particle 16 to form the capsule granule 10. Under condition of closely aggregating the capsule granules 10, the fine particles 17 are melted with plasma sintering method, etc., to make base layer 18 integrating mutually the fine particles 17, and the basis particles 16 are dispersed in the base layer 18 to form Al2O3 dispersion type titanium formed body 19. By suitably machining the surface 20 of this formed body 19, artificial bond or root of tooth having affinity to human organism and excellent in wt. and toughness, is obtd.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a PSA (prostatic specific antigen)-derived HLA-A24 (antigen) binding cancer antigen peptide, a polynucleotide encoding the peptide and a CTL (cytotoxic lymphocyte) inducer containing the peptide or the polynucleotide.  &lt;P&gt;SOLUTION: The peptide comprises any amino acid sequence selected from specific 9 kinds of amino acid sequences. The polynucleotide encodes the peptide. The cancer vaccine contains the peptide or the polynucleotide. The antibody against the peptide is obtained. The method for producing the peptide is provided.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
Beta-adrenergic blocking propanolamine derivs. Title cpds. of formula (I) (where R&#39; is carboxyamido (pref. acetamido), lower alkoxycarbonylamino or carbamoyl which can be separated from the phenyl ring by a methylene or ethylene groups; R2 and R3 are H or lower alkyl; R4 is carboxyamido, sulphonamido, lower alkoxycarbonyl: amino, carbamoyl or sulphamoyl which can be separated from the phenyl ring by a methylene or ethylene group; R5 is H, lower alkyl, lower alkanoyl or benzyl, X is O or S; Y is O, S, SO, SO2, NH or a direct bond; n is 1,2 or when Y is a direct bond, also O or 4; and rings A and B may be further substd. by one or more halogen atoms or lower alkyl, alkenyl, alkoxy or alkenoxy groups) and their pharmaceutically tolerable acid addition salts, as well as aldehyde condensation products of (I; R5 = H) and esters in which the 2-hydroxy group is esterified with a lower alkane carboxylic acid. Their beta-adrenergic blocking effect is stronger on cardiac than on peripheral receptors and they are useful for heating e.g. angina pectoris and cardiac arrhythmias.
FIELD: medicinal immunology. SUBSTANCE: mice are intravenously injected (into retroorbital venous plexus) with mink&#39;s serum at quantity of below 0.1 ml/mouse that leads to murine death. To study the action of inhibiting agent the latter is introduced simultaneously with mink&#39;s serum or 2 min before its injection. Its efficiency is determined by that its minimal introduced quantity which eliminates animal&#39;s death. The present innovation widens the number of techniques used in studying immune system in mammalians. EFFECT: higher efficiency. 1 ex, 1 tbl